机构：[1]Eye Hospital and Institute for Advanced Study on Eye Health and Diseases, Institute for clinical Data Science, Wenzhou Medical University, Wenzhou, China.[2]State Key Laboratory of Macromolecular Drugs and Large-Scale Preparation, Wenzhou Medical University, Wenzhou, China.[3]Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院[4]Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.中山大学附属第二医院[5]Institute for AI in Medicine and faculty of Medicine, Macau University of Science and Technology, Macau, China.[6]Guangzhou National Laboratory, Guangzhou, China.[7]National Institute of Biological Sciences, Beijing, China.[8]Eye and Vision Innovation Center, Eye Valley, Wenzhou, China.[9]Cardiovascular Research Institute, Stanford University, Stanford, CA, USA.
Drug development is a complex and time-consuming endeavor that traditionally relies on the experience of drug developers and trial-and-error experimentation. The advent of artificial intelligence (AI) technologies, particularly emerging large language models and generative AI, is poised to redefine this paradigm. The integration of AI-driven methodologies into the drug development pipeline has already heralded subtle yet meaningful enhancements in both the efficiency and effectiveness of this process. Here we present an overview of recent advancements in AI applications across the entire drug development workflow, encompassing the identification of disease targets, drug discovery, preclinical and clinical studies, and post-market surveillance. Lastly, we critically examine the prevailing challenges to highlight promising future research directions in AI-augmented drug development.
基金：
Wenzhou Eye Hospital, Institute for Advanced Study on Eye Health and Disease, Wenzhou Medical University; National Natural Science Foundation of China [W2431057, T2221004, 22277085, 82404087, YW-SLJC0201, GZNL2024A01005]; National Key R&D Program of China [2023YFF1204905]; Tianfu Jincheng Laboratory Foundation [TFJC2023010009]; Guangzhou Science and Technology Project [2023A03J0722]; New Cornerstone Science Foundation; National Institutes of Health [R01-GM129325]; Office of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases
语种：
外文
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2025]版：
无
最新[2023]版：
大类|1 区医学
小类|1 区生化与分子生物学1 区细胞生物学1 区医学：研究与实验
JCR分区：
出版当年[2025]版：
无
最新[2023]版：
Q1BIOCHEMISTRY & MOLECULAR BIOLOGYQ1CELL BIOLOGYQ1MEDICINE, RESEARCH & EXPERIMENTAL
第一作者机构：[1]Eye Hospital and Institute for Advanced Study on Eye Health and Diseases, Institute for clinical Data Science, Wenzhou Medical University, Wenzhou, China.[2]State Key Laboratory of Macromolecular Drugs and Large-Scale Preparation, Wenzhou Medical University, Wenzhou, China.
共同第一作者：
通讯作者：
通讯机构：[1]Eye Hospital and Institute for Advanced Study on Eye Health and Diseases, Institute for clinical Data Science, Wenzhou Medical University, Wenzhou, China.[2]State Key Laboratory of Macromolecular Drugs and Large-Scale Preparation, Wenzhou Medical University, Wenzhou, China.
推荐引用方式(GB/T 7714)：
Zhang Kang,Yang Xin,Wang Yifei,et al.Artificial intelligence in drug development[J].NATURE MEDICINE.2025,doi:10.1038/s41591-024-03434-4.
APA：
Zhang, Kang,Yang, Xin,Wang, Yifei,Yu, Yunfang,Huang, Niu...&Yang, Shengyong.(2025).Artificial intelligence in drug development.NATURE MEDICINE,,
MLA：
Zhang, Kang,et al."Artificial intelligence in drug development".NATURE MEDICINE .(2025)
医学